Patents Assigned to UCB Pharma GmbH
-
Patent number: 12071404Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.Type: GrantFiled: October 20, 2021Date of Patent: August 27, 2024Assignee: UCB Pharma GmbHInventors: Christa E. Mueller, Cécile Pegurier, Michael Louis Robert Deligny, Ali El-Tayeb, Joerg Hockemeyer, Marie Ledecq, Joël Mercier, Laurent Provins, Nader M. Boshta, Sanjay Bhattarai, Vigneshwaran Namasivayam, Mario Funke, Lukas Schwach, Sabrina Gollos, Daniel Von Laufenberg, Anaïs Barré
-
Patent number: 11976056Abstract: The present application relates to alkoxy-substituted pyridinyl indolsulfonamides. The compounds are negative GPR17 modulators and have utility in the treatment of various GPR17 associated disorders.Type: GrantFiled: June 19, 2019Date of Patent: May 7, 2024Assignee: UCB PHARMA GMBHInventors: Cecile Pegurier, Laurent Provins, Emre M. Isin, Marie Ledecq
-
Patent number: 11939319Abstract: The present invention relates to pyridinyl and pyrazinyl-(aza)indolsulfonamides having GPR17 modulator activity. The compounds have utility in the treatment of a variety of GPR17-associated disorders.Type: GrantFiled: June 18, 2019Date of Patent: March 26, 2024Assignee: UCB PHARMA GMBHInventors: Cecile Pegurier, Laurent Provins, Alvaro Cardenas, Marie Ledecq, Christa E. Mueller, Joerg Hockemeyer, Ali El-Tayeb, Nader Boshta, Mahmoud Rashed
-
Patent number: 11820746Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.Type: GrantFiled: January 5, 2022Date of Patent: November 21, 2023Assignee: UCB PHARMA GMBHInventors: Christa E. Mueller, Cécile Pegurier, Michael Louis Robert Deligny, Ali El-Tayeb, Joerg Hockemeyer, Marie Ledecq, Joël Mercier, Larurent Provins, Nader M. Boshta, Sanjay Bhattarai, Vigneshwaran Namasivayam, Mario Funke, Lukas Schwach, Sabrina Gollos, Daniel Von Laufenberg, Anaïs Barré
-
Patent number: 11345662Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.Type: GrantFiled: December 27, 2017Date of Patent: May 31, 2022Assignee: UCB Pharma GmbHInventors: Christa E. Mueller, Cécile Pegurier, Michael Louis Robert Deligny, Ali El-Tayeb, Joerg Hockemeyer, Marie Ledecq, Joël Mercier, Laurent Provins, Nader M. Boshta, Sanjay Bhattarai, Vigneshwaran Namasivayam, Mario Funke, Lukas Schwach, Sabrina Gollos, Daniel Von Laufenberg, Anaïs Barré
-
Publication number: 20190345104Abstract: Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.Type: ApplicationFiled: December 27, 2017Publication date: November 14, 2019Applicant: UCB Pharma GmbHInventors: Christa E. MUELLER, Cécile PEGURIER, Michael Louis Robert DELIGNY, Ali EL-TAYEB, Joerg HOCKEMEYER, Marie LEDECQ, Joël MERCIER, Laurent PROVINS, Nader M. BOSHTA, Sanjay BHATTARAI, Vigneshwaran NAMASIVAYAM, Mario FUNKE, Lukas SCHWACH, Sabrina GOLLOS, Daniel von LAUFENBERG, Anaïs BARRÉ
-
Publication number: 20190314294Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a nom-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: ApplicationFiled: May 23, 2019Publication date: October 17, 2019Applicants: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael WOLFF, Christoph ARTH, Luc QUERE, Walter MÜLLER
-
Patent number: 10350174Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: GrantFiled: May 17, 2018Date of Patent: July 16, 2019Assignees: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Publication number: 20190054009Abstract: A modified release formulation of lacosamide suitable for once-daily administration.Type: ApplicationFiled: August 21, 2018Publication date: February 21, 2019Applicant: UCB Pharma GmbHInventors: Willi CAWELLO, Martin Alexander SCHUBERT
-
Publication number: 20190008758Abstract: A modified release formulation of lacosamide suitable for once-daily administration.Type: ApplicationFiled: July 5, 2018Publication date: January 10, 2019Applicant: UCB Pharma GmbHInventors: Willi CAWELLO, Martin Alexander SCHUBERT
-
Patent number: 10149818Abstract: A modified release formulation of lacosamide suitable for once-daily administration.Type: GrantFiled: December 1, 2011Date of Patent: December 11, 2018Assignee: UCB PHARMA GMBHInventors: Willi Cawello, Martin Alexander Schubert
-
Patent number: 10130589Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: GrantFiled: January 31, 2018Date of Patent: November 20, 2018Assignees: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Publication number: 20180263921Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: ApplicationFiled: May 17, 2018Publication date: September 20, 2018Applicants: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael WOLFF, Christoph ARTH, Luc QUERE, Walter MÜLLER
-
Publication number: 20180221300Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and and C) optionally an additional skin contact layer.Type: ApplicationFiled: May 20, 2015Publication date: August 9, 2018Applicants: LTS LOHMANN Therapie-Systeme AG, UCB Pharma GmbHInventors: Marco Emgenbroich, Johannes Josef Leonhard, Kristina Kassner, Aurélia Lappert
-
Publication number: 20180147154Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: ApplicationFiled: January 31, 2018Publication date: May 31, 2018Applicants: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AGInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Patent number: 9925150Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.Type: GrantFiled: December 22, 2010Date of Patent: March 27, 2018Assignees: LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbHInventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
-
Patent number: 9630908Abstract: The present invention provides a process for the preparation of lacosamide in substantially optically pure form, which in one aspect comprises the following steps: (i) resolution of O-methyl-D,L-serine to provide O-methyl-D-serine in substantially optically pure form; (ii) acetylation of O-methyl-D-serine thereby obtained to provide the N-acetyl 10 derivative thereof in substantially optically pure form; (iii) activating the carboxy group of the compound thereby obtained; and (iv) reacting the compound thereby obtained with benzylamine.Type: GrantFiled: August 17, 2015Date of Patent: April 25, 2017Assignee: UCB Pharma GmbHInventors: Alain Merschaert, Christophe Joseph Szczepaniak, Joerg Hamann, Ralf Kanzler
-
Publication number: 20170105945Abstract: Transdermal therapeutic system for the transdermal administration of rotigotine containing an therapeutically effective amount of rotigotine base in a self-adhesive layer structure, comprising A) a backing layer, and B) a rotigotine-containing biphasic layer, the bi phasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or a polymer mixture, and b) an inner phase having a composition comprising rotigotine base, wherein the inner phase forms dispersed deposits in the outer phase, and wherein the inner phase comprises i. rotigotine base, and ii.Type: ApplicationFiled: May 20, 2015Publication date: April 20, 2017Applicants: LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbHInventors: Marc Emgenbroich, Elke Klein, Heike Kluth
-
Publication number: 20170079932Abstract: Use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, wherein the inner phase comprises the additive and an active agent dissolved therein, wherein the additive has a higher affinity to water than to the active agent, for the control of the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, wherein the maintenance of the permeation rate is proportional to the amount of active agent in the biphasic layer.Type: ApplicationFiled: May 20, 2015Publication date: March 23, 2017Applicants: LTS Lohmann Therapie-Systeme AG, UCB Pharma GmbHInventors: Marco Emgenbroich, Johannes Josef Leonhard, Hans-Michael Wolff
-
Publication number: 20170035733Abstract: The present application relates to a fixed dose combination comprising lacosamide and levetiracetam, as well as to dosage regimens including such fixed dose combinations. The fixed dose combinations are suitable for the oral or parenteral treatment of various diseases, including in particular epilepsy and/or epileptic seizures.Type: ApplicationFiled: November 28, 2014Publication date: February 9, 2017Applicant: UCB PHARMA GMBHInventors: Benjamin THOORENS, Andrew FADDEN, René Pierre PINARD, Florent ROBIN, Martin Alexander SCHUBERT, Frank TENNIGKEIT, Serge CUYPERS